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Summary: Patients with non-dialysis CKD can mount similar responses to vaccination as controls. 
Subtle changes in lymphocyte phenotype are seen in CKD when controlled for effect of CMV. Latent 

























Patients with chronic kidney disease (CKD) are more prone to severe infection. Vaccination is a key 
strategy to reduce this risk. Some studies suggest vaccine efficacy may be reduced in patients with 
CKD, despite preserved maintenance of long-term responses to some pathogens and vaccines. Here, 
we investigated immune responses to two vaccines in patients with CKD in order to identify 
predictors of immunological responsiveness. 
Methods 
Individuals >65 years old, with or without non-dialysis CKD (n=36 and 29, respectively), were 
vaccinated with a non-adjuvanted seasonal influenza vaccine (T-dependent) and Pneumovax23 
(PPV23, T-independent). Humoral responses were measured at baseline, day 28 and 6 months. 
Lymphocyte subset and plasmacell/blast analyses were performed using flow cytometry. CMV 
serotyping was assessed by ELISA.  
Results 
Only modest responsiveness was observed to both vaccines, independent of CKD status (25% 
adequate response in controls versus 12-18% in CKD group). Unexpectedly, previous immunization 
with PPV23 (median 10-year interval) and CMV seropositivity were associated with poor PPV23 
responsiveness in both study groups (p<0.001 and 0.003 respectively, multi-variable linear 
regression model). Patients with CKD displayed expanded circulating populations of Th2 and Tregs, 
which were unrelated to vaccine responses. Despite fewer circulating B cells, patients with CKD were 




















Patients with non-dialysis CKD can respond similarly to vaccines as age and sex matched healthy 
individuals. CKD patients display an immune signature that is independent of vaccine 
responsiveness. Prior PPV23 immunization and CMV infection may influence responsiveness to 
vaccination.  
 






















Chronic kidney disease (CKD) is common, affecting approximately 8% of the UK population, and 
prevalence increases with advancing age[1]. Patients with CKD have an elevated risk of infection, 
which increases with disease severity and accounts for 20% of mortality[2, 3]. The aetiology of this 
increased risk is not fully understood. Vaccination is an obvious potential preventive strategy, but 
lower rates of seroconversion and impaired maintenance of humoral vaccine responses are reported 
in CKD[4, 5]. However, humoral responses to historically encountered antigens, such as tetanus or 
diphtheria toxoids, are similar between patients with CKD and age-matched controls[6]. Moreover, 
antibody function (e.g. killing of Salmonella enterica) can be maintained in patients with CKD[6].  
Other factors are associated with increased risk of infection, including age[7]. Previous exposure to 
plain polysaccharides may cause hyporesponsiveness to subsequent vaccination, hence current 
guidance advises revaccination after 5 years[8]. Furthermore, previous infection with 
cytomegalovirus (CMV) can also negatively impact vaccine responses in healthy older adults[9-12], 
although this has not been examined in CKD. Therefore, multiple other factors could influence 
vaccine responsiveness in patients with CKD.  
In this study, we evaluated responsiveness to vaccination in a carefully matched cohort of older 
patients with and without non-dialysis CKD. We found only subtle differences between the study 
groups. CMV and previous 23-valent pneumococcal polysaccharide (PPV23) vaccination emerged as 
the strongest predictors of vaccine responsiveness, rather than CKD. As such, appreciation of both 
disease-specific and environmental immune-modulating factors is needed to optimise vaccination 





















Patients with CKD and healthy controls were recruited to a prospective observational cohort study 
(clinicaltrials.gov ID:NCT02535052) between June 2015 and January 2018 at University Hospitals 
Birmingham NHS Foundation Trust (UHBFT), Birmingham, UK. Edgbaston Research Ethics Committee 
approved the study (ref:15/WM/0057). All participants gave written informed consent. 
Subjects were aged ≥65 years, without immune-mediated disease or malignancy within the 
preceding 5 years. Patients not requiring dialysis, with laboratory eGFR 15-60ml/min were recruited 
from UHBFT CKD outpatient clinics. Controls were relatives of patients or from the wider 
community, with eGFR>60ml/min. Demographics and baseline clinical information were collected 
from electronic clinical records and vaccination history from primary care records. Individuals that 
had received PPV23 within 5 years were excluded 
Participants were vaccinated with trivalent inactivated influenza (TIV) and PPV23 intramuscularly as 
per manufacturer instructions (PPV23–Merck,USA; TIV–Sanofi,France). PPV23 contains capsular 
polysaccharides for 23 serotypes of Streptococcus pneumoniae. TIV contained haemagglutinin 
antigens (HAs) from 2 influenza A strains and one B strain, which varied between years based on 
WHO northern hemisphere recommendations[13].  
Peripheral blood was collected at baseline, days 7, 28 and month 6 after vaccination. Serum was 
separated from blood and frozen at −20°C. Peripheral blood mononuclear cells (PBMCs) were 
separated by density gradient centrifugation (Ficoll-Paque PLUS, GE Healthcare) and either used 
immediately or frozen for batched analysis. Baseline and/or month 6 PBMCs were used for 



















Influenza haemagglutination inhibition assay (HAI) 
NIBSC laboratories (Potters Bar, UK) performed the influenza HAI assay using standard methods as 
previously described[14].  All test sera were tested twice against the relevant vaccine strains from 
each vaccine season.  
Measurement of IgG to pneumococcal polysaccharides  
Concentrations of IgG against 12 PPV23 antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) were 
determined in the UHBFT Clinical Immunology Laboratory using a validated multiplex assay, as 
previously described[15]. To minimize inter-assay variability, samples were processed in batches 
with all timepoints from an individual included in the same assay. 
Vaccine response adequacy criteria 
Adequate responses to influenza HAs and pneumococcal polysaccharides (PnPS) were defined as the 
conversion from a non-protective to protective titre (TIV: HAI≥40; PPV23: serotype-specific anti-PnPS 
IgG titre≥0.35μg/ml)[13, 16]). If pre-vaccination titres were protective, responses were considered 
adequate if a 2-fold (for PPV23) or 4-fold (for TIV) increase in titre was seen at day 28 post-
vaccination[13, 16]. An adequate response to the vaccine as a whole was defined as an adequate 
response to 2/3 TIV strains or 8/12 PPV23 serotypes. 
Measurement of CMV-specific IgG 






















Flow cytometric phenotyping of lymphocytes was performed using an LSR Fortessa instrument and 
results analysed using FACSDiVa software (v8.0; BD Biosciences, UK). Cells were incubated in BD 
BrilliantTM staining buffer for 30 minutes with pre-titrated volumes of fluorochrome-conjugated 
antibodies (Supplementary Table 1). Intracellular staining for cytokines and transcription factors was 
performed using a FoxP3/Transcription Factor Staining Buffer Kit, as per manufacturer instructions 
(eBioscience, USA). Unstimulated PBMCs were used to set negative gates and FMO controls were 
used where required. Representative gating strategies are shown in Supplementary Figures 2,5 and 
7. 
All phenotyping was performed using cryopreserved cells, except for surface chemokine receptor 
staining to define Th1/2/17/fh CD4 populations, which was done on fresh PBMCs. Th1 and Th2 CD4 
phenotype were also defined by cytokine production: cryopreserved PBMCs were cultured for 18 
hours at 37°C, 5% CO2, with 5µg/ml plate-bound aCD3, soluble aCD28 and aCD49d (Supplementary 
Table 1) in complete RPMI medium with brefeldin A and monensin (eBioscience, USA). 
Statistics 
Statistical analyses were performed using Prism (version 7, GraphPad, USA) and SPSS software 
(version 24, IBM, USA). Continuous data were tested for Normality (using Shapiro-Wilk or 
Kolmogorov Smirnoff tests) and groups were compared using parametric (unpaired/paired t-test, 
ANOVA) and non-parametric methods (Mann-Whitney test) as appropriate. Categorical data were 
compared using Fisher’s exact or Chi square tests. Correlations between continuous data were 
assessed using Pearson’s and Spearman’s rank test as appropriate. Multivariate analysis on 
continuous data (Normalised as appropriate) was performed using linear regression modelling. In all 
statistical analyses, two-tailed p<0.05 was considered statistically significant. Bonferroni correction 





















Sixty-five individuals were vaccinated: 29 controls and 36 patients with CKD. Four individuals (1 
control, 3 patients with CKD) were excluded from the final analysis as they either developed health 
conditions that met study exclusion criteria (n=2) or were lost to follow-up (n=2). Patients with CKD 
were similar in age and gender as controls, but had greater co-morbidity (Table 1).  Patients with 
CKD had a median eGFR of 21ml/min. Compared to controls, patients with CKD were anaemic and 
had a significantly higher white cell count (WCC), neutrophil count and CRP (Table 1). The prevalence 
of latent CMV (defined by CMV IgG seropositivity) and serum levels of CMV-specific IgG in 
seropositive individuals were not significantly different between disease groups. 
Inadequate vaccine responses are observed in study participants 
irrespective of CKD 
At baseline, controls and patients with CKD had similar proportions of individuals with protective HAI 
titres against any of the 3 TIV influenza strains and protective anti-PnPS IgG concentrations for any 
of the 12 serotypes tested (Table 2). The proportion of individuals with protective titres to both TIV 
and PPV23 antigens increased following vaccination in both groups.  Whole vaccine responses were 
modest for both TIV and PPV23, and overall responses were similar in controls and patients with CKD 
(Table 2). Individuals with adequate vaccine responses to either vaccine at day 28 maintained them 
at month 6, with no differences between the groups (TIV: 80% (n=16) controls, 67% (n=14) patients 
with CKD; PPV23: 86% (n=6) controls, 100% (n=6) patients with CKD). Baseline strain-specific HAI 
titres and serotype-specific Pn IgG concentrations were similar between the groups (Supplementary 
Tables 2,3). Patients with CKD demonstrated a similar magnitude of increase in strain-specific HAI 



















(defined by the antibody maintenance ratio (AMR): month 6/day 28 titre) as controls following 
vaccination (Supplementary Table 2). PPV23 vaccination significantly increased serotype-specific 
anti-PnPS IgG concentrations from baseline to day 28 for all 12 serotypes tested in both controls and 
patients with CKD and to a similar degree. Maintenance of post-vaccination anti-PnPS IgG 
concentrations (AMR) was also similar between the groups (Supplementary Table 3). Therefore, CKD 
status did not influence the magnitude or longevity of these vaccine responses. 
Age, previous PPV23 vaccination and CMV predict PPV23 vaccine response 
Poorer responsiveness to both vaccines was significantly associated with older age (Supplementary 
Figure 1), but not with CKD. As latent CMV has previously been associated with 
immunosenescence[9], we then examined associations between CMV and vaccine responses. No 
differences were seen in whole TIV or influenza strain-specific ARRs between CMV seronegative and 
seropositive study participants (data not shown). However, CMV seropositive individuals 
demonstrated lower Pn serotype-specific ARRs and significantly poorer humoral responses to whole 
PPV23 when compared to their CMV seronegative counterparts (Figure 1:A,B).  
Given the significant differences in previous PPV23 exposure between the disease groups (Table 1), 
we then examined the impact of previous PPV23 vaccination on humoral responses across the whole 
study population. Revaccinees had significantly lower ARRs for 6 of 12 serotypes tested (Pn 1, 3, 5, 
6b, 18c and 23F) and to whole PPV23, independent of disease status (Figure 1:C,D). Although 
revaccinees were significantly older than vaccine-naïve individuals (median 78 years, IQR 9 versus 
70, IQR 4; Mann-Whitney 2-tailed p<0.0001), previous PPV23 vaccination remained a significant 
predictor of lower PPV23 ARR, independent of age, gender, smoking and CKD status in a linear 
regression model (p=0.02). Overall, specific anti-PnPs IgG titres were significantly greater at month 6 
following PPV23 vaccination than at baseline (Supplementary Table 3). However, only 60% of 
revaccinees maintained month 6 Pn serotype-specific IgG concentrations above pre-vaccination 



















tailed p<0.01). Both CMV seropositivity and previous PPV23 vaccination significantly predicted lower 
PPV23 ARR in a multi-variable linear regression model, independent of age, gender, smoking or CKD 
status (p<0.001 for PPV23 status, p=0.003 for CMV status, p=0.004 for synergistic interaction term).  
CMV seropositivity and associated T cell phenotypes, not CKD, correlate 
with vaccine responses 
The proportion of circulating T lymphocytes, together with the CD4/8 ratio, were similar between 
patients with CKD and controls (Figure 2:A,B; Supplementary Figure 2). Circulating proportions of 
CD45RA- and CCR7-expressing naïve/memory and CD27-/28- or CD57+KLRG1+ terminally 
differentiated CD4+ and CD8+ T cells were also similar between the groups (Figure 2:C-E and 
Supplementary Figures 3,4), as were populations of “Tfh-like” (CXCR5
+), “Th17-like” 
(CCR4+CCR6+CXCR3-) and Th1 CD4
+ T cells (CCR4-CCR6-CXCR3+ or IFNg+Tbet+) (Figure 2:F-I; 
Supplementary Figure 5). However, Th2 (CCR4
+CCR6-CXCR3- or GATA3+IL-4+) and Treg (CD25
highFoxP3+) 
CD4+ T cells were significantly expanded in patients with CKD compared to controls (Figure 2:J-L; 
Supplementary Figure 6).  
As expected with T-independent antigens, we did not observe any significant associations between 
circulating T cell populations and PPV23 ARR. TIV ARR was not related to circulating Th2 or Treg 
populations, but a significant inverse association was seen with proportions of terminally 
differentiated CD4+ T cells (Figure 3:A-C). Both CKD and CMV have previously been associated with 
expansions of such CD4+ T cell subsets, most notably CD4+CD28null cells[18, 19]. CMV seropositivity, 
not CKD status, was the main correlate of the CD4/8 ratio and the size of CD4+CD28null and other 
terminally differentiated T cell populations (Figure 3:D-G; Supplementary Figure 4). CMV 
seropositivity was not associated with the size of Th2 or Treg populations (Figure 3:I,J).  
In keeping with previous data[20, 21], patients with CKD had a significantly lower proportion of 
circulating B cells (relative to total circulating lymphocytes) than controls (Figure 4:A). Despite this, 



















post-vaccination to the same degree as controls (Figure 4:C-F), reflecting the similar humoral vaccine 
responses observed. The fold change in circulating PC/B proportion of total B cells (day 7/day 0) 
significantly correlated with both PPV23 and TIV ARR (Figure 4:G,H). CMV seropositivity was 
associated with smaller expansions of PC/Bs at day 7 post-vaccination (Figure 4:I), which were also, 
in turn, associated with larger proportions of CD4+CD28null T cells (Figure 4:J).  
Discussion 
This prospective study in older adults, with and without CKD, examined humoral responses to 
simultaneous vaccination with TIV and PPV23 alongside cross-sectional profiling of circulating 
lymphocyte subsets. Vaccine responses were modest overall and similar between disease groups, 
consistent with previous work showing that functional antibody responses can be elicited in older 
patients with CKD[6]. In keeping with this, both groups also demonstrated similar fold-increases in 
circulating PC/Bs after vaccination. This shows that B cell responsiveness is maintained in CKD, 
despite the lower proportion of circulating B cells detected compared to controls. Older age, 
previous PPV23 vaccination and CMV seropositivity were predictors of poor vaccine response, 
whereas CKD was not. Previous studies investigating TIV and PPV23 responsiveness in adults with 
non-dialysis CKD have reported variable results[22-24], which may reflect heterogeneity of 
populations studied. Indeed, many such studies included patients on dialysis, which is known to 
exert independent immunomodulatory effects[25, 26], and were less controlled for age and 
frailty[27]. Our findings are paralleled by a recent large epidemiological study that found responses 
to influenza and pneumococcal vaccines were poor in older patients with diabetes and not affected 
by CKD, unless patients required dialysis[28]. 
Surprisingly, patients with CKD had no reduction in proportions of circulating total T cells or other 
phenotypic differences previously described[29-31]. However, CMV seropositivity strongly 
correlated with a higher frequency of Th1 cells and terminally differentiated CD4



















both controls and patients with CKD. These associations with CMV are known[32], but we also 
observed that expansions of CD4+CD28null T cells were negatively correlated with vaccine response.  
Primary CMV infections typically occur in childhood and are clinically non-specific or asymptomatic, 
making the timing of CMV acquisition difficult[33]. Following infection, the virus establishes a 
persistent state termed “latent”, characterised by periodic episodes of subclinical reactivation 
triggered by biological stressors[18]. Such reactivations are transient and rarely detectable in 
blood[34]. Although we did not evaluate CMV viraemia in our study population, reports suggest that 
frequent episodes of subclinical CMV reactivation are associated with higher levels of CMV-specific 
IgG[34]. In our study, prevalence of CMV seropositivity and titres of CMV-specific IgG were similar in 
controls and patients with CKD, suggesting a similar CMV burden in both study groups. This is likely 
to explain the differences in our results from other studies, which do not control for the 
immunomodulating effects of CMV.  
Published data on whether CMV seropositivity correlates with vaccine responses is inconsistent[35].  
However, several studies suggest that the magnitude of the immune response to latent CMV 
infection is more important than simply CMV seropositivity. In vitro studies suggest that inflation of 
the CMV memory response, including expansions of potentially cytotoxic, but poorly replicative 
CD4+CD28null T cells is associated with a progressive decline in the overall functional capacity of T 
cells[34, 36]. We identified negative correlations between CD4+CD28null T cells and humoral 
responses to a TD vaccine (TIV), together with day 7 PC/B expansions. CMV seropositivity was also 
associated with poorer responses to the TI vaccine (PPV23) in the study population as a whole. CMV-
associated impairment of B cell responses has previously been reported with regard to TD 
vaccines[10, 11], but not for TI vaccines. There are several potential mechanisms by which CMV 
could impact TI antigen responses and further studies are needed to investigate these non-
exhaustive options. For example, Tfh cells are known to play a significant role in generating long-



















CMV may result in Tfh dysfunction. In addition, CMV infects cells of the monocyte lineage[18] and 
secretion of B cell survival factors by macrophages is known to promote TI class switch 
recombination[38]. As such, the influence of CMV in TI responses may be through dysfunction of 
mechanisms supporting plasma cell differentiation and/or survival. Our findings suggest that latent 
CMV infection could play a greater role in modulating immune responses to vaccines in older adults, 
with and without chronic disease, than is currently appreciated. A recent proof-of-concept study in 
patients with ANCA-associated vasculitis showed improved vaccine responses following suppression 
of CMV reactivation[34]. The interesting associations we observed between CMV serostatus and 
vaccine responses were, however, assessed post-hoc as exploratory analyses and therefore require 
confirmation in future studies. 
Responses to PPV23 were lower in those who had previously received PPV23, despite a median 10 
year interval between immunizations. This is in keeping with immune hypo-responsiveness to repeat 
plain polysaccharide vaccination[39] and consistent with previous studies showing only marginal 
reductions in morbidity and mortality with PPV23 vaccination in older adults[40]. Interestingly, both 
CMV seropositivity and previous PPV23 vaccination were significant predictors of PPV23 mean ARR, 
independent of age, gender, smoking and CKD status. Although we controlled for multiple 
confounders that could explain the reduced responsiveness with repeat PPV23 immunization, there 
may be other unmeasured contributory factors. As such, further studies are needed to determine 
the impact of repeat PPV23 vaccination and evaluate whether conjugate pneumococcal vaccines 
may be advantageous in high risk individuals.  
Limitations of the study include cohort size and immunisation over 3 influenza seasons, which may 
have impacted our ability to detect subtle differences in humoral responses. However, patients with 
CKD were well-controlled for age and gender. The majority of the CKD cohort had moderate/severe 
renal impairment with significant proteinuria, and clinical features representative of the wider CKD 



















therapy and autoimmune disease) were excluded through strict patient selection, we were not able 
to control for all potential confounders in this study. Our study has only investigated lymphocyte 
function through antibody responses and cytokine production. Thus, it is possible that defects in 
antigen presentation and innate immune system activation could be present in CKD-associated 
immune dysfunction and may be more important than lymphocyte function. The evaluation of the 
impact of CMV serostatus and prior PPV23 vaccination on vaccine responses constitute exploratory 
analyses and our findings, therefore, require independent confirmation in further studies that 
should also include investigation of potential mechanisms, which we did not perform as part of this 
work.  
This study and our previous work[6] suggest that in order to understand the aetiology of increased 
infection risk in CKD we need to examine how the adaptive and innate immune systems interact to 
control infection. We suggest that future studies of immune function in this field be controlled for 
the presence of latent CMV infection, due to its large effect on shaping immune phenotypes, and 
that the effect of subclinical episodes of CMV reactivation on immune responses is investigated. 
Finally, our observation of significant and long-lasting polysaccharide hyporesponsiveness in older 
adults, with and without chronic disease, suggests that further studies are required to examine the 
immunological and clinical impact of  repeated plain polysaccharide versus conjugate anti-
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Age, years 74 (11) 75 (11) 0.28a 
Male: n (%) 15 (54) 23 (70) 0.29b 
White ethnicity: n (%) 28 (100) 30 (91) 0.24b 
Current/ex-smoker: n (%) 10 (36) 25 (76) 0.002b 
Received TIV in preceding season: n (%) 24 (86) 30 (91) 0.69b 
Previous PPV23: n (%) 17 (61) 29 (88) 0.02b 
Time from previous PPV23 (years) 9.9 (5.0) 11.0 (4.2) 0.26a 
Ischemic/hypertensive nephropathy - 14 (42) - 
Diabetic nephropathy - 5 (16) - 
Obstructive uropathy - 2 (6) - 
Other* - 2 (6) - 
Unclear# - 10 (30) - 
Charlson Comorbidity Index 1 (2) 5 (3) <0.0001a 
DM: n (%) 1 (4) 22 (67) <0.0001b 
HTN: n (%) 9 (32) 32 (97) <0.0001b 
CVD (incl IHD, CVA/TIA, PVD, CCF, arrhythmias): n (%) 7 (25) 25 (76) 0.0001b 
Number of medications per person 2 (3) 9 (4) <0.0001a 
Participants with 5 medications (polypharmacy): n (%) 4 (14) 32 (97) <0.0001b 
Hb, g/L 140 (9) 115 (19) <0.0001a 
WCC, 109/l 6.0 (2.9) 7.2 (3.4) 0.005a 



















Lymphocytes, 109/l 1.6 (1.1) 1.3 (1.0) 0.13a 
Platelets, 109/l 213 (53) 191 (79) 0.15a 
Neutrophil/lymphocyte ratio 2.1 (0.8) 3.8 (2.4) <0.0001a 
eGFR, ml/min 77 (16) 21 (13) <0.0001a 
ACR, mg/mmol 0.5 (1.7) 28.8 (153.5) <0.0001a 
hsCRP, mg/l 0.8 (1.1) 5.1 (5.1) <0.0001a 
HbA1c, mmol/mol 36.5 (4.0) 50.5 (19.8) <0.0001a 
CMV seropositive: n (%) 17 (61) 27 (82) 0.09b 
Anti-CMV IgG titre (seropositive only), log10(AU) 2.1 (0.65) 2.2 (0.60) 0.74
c 
Median and IQR shown unless stated. Significance level is p<0.05 (highlighted in bold). CKD – chronic kidney disease, DM – diabetes 
mellitus, HTN - hypertension, CVD – cardiovascular disease, IHD – ischaemic heart disease, CVA – cerebrovascular accident, TIA – transient 
ischaemic attack, PVD – peripheral vascular disease, CCF – congestive cardiac failure, CI – confidence interval, Hb - haemoglobin, WCC – 
white cell count, eGFR – estimated glomerular filtration rate, ACR – albumin/creatinine ratio, hsCRP – highly sensitive C-reactive protein, 
HbA1c – glycated haemoglobin, CMV - cytomegalovirus, TIV – trivalent influenza vaccine, PPV23 – 23-valent pneumococcal polysaccharide 
vaccine. *1 lithium toxicity, 1 congenital single kidney; #no clearly defined aetiology, but with multiple co-morbidities known to cause renal 




















Table 2. Adequacy of vaccine response and population “protection” against influenza and 











No significant differences were observed between controls and CKD for any of the parameters listed when α was adjusted for multiple 
comparisons (Bonferroni correction). N (%) shown; full definitions of “protection” and humoral response “adequacy” can be found in 
Methods. 
  











at Day 28 
“Adequate” 
response 
Influenza strains  A/H1N1 13 (46) 22 (79) 12 (43) 14 (42) 22 (67) 9 (27) 
A/H3N2 17 (61) 23 (82) 9 (32) 26 (79) 28 (85) 6 (18) 
B 6 (21) 10 (36) 4 (14) 3 (9) 6 (18) 3 (9) 
2 of 3 strains  11 (39) 20 (71) 7 (25) 12 (36) 21 (64) 4 (12) 
Pn serotypes                     1 12 (43) 20 (71) 17 (61) 10 (30) 17 (52) 11 (33) 
3 4 (14) 13 (46) 10 (36) 4 (12) 5 (15) 2 (6) 
4 7 (25) 16 (57) 10 (36) 11 (33) 14 (42) 7 (21) 
5 17 (61) 24 (86) 17 (61) 17 (52) 20 (61) 10 (30) 
6b 13 (46) 20 (71) 11 (39) 19 (58) 21 (64) 9 (27) 
7f 22 (79) 26 (93) 13 (46) 25 (76) 29 (88) 10 (30) 
9V 20 (71) 25 (89) 11 (39) 20 (61) 25 (76) 7 (21) 
14 26 (93) 27 (96) 8 (29) 31 (94) 31 (94) 6 (18) 
18c 23 (82) 26 (93) 14 (50) 26 (79) 29 (88) 13 (39) 
19A 19 (68) 22 (79) 9 (32) 22 (67) 23 (70) 13 (39) 
19F 22 (79) 27 (96) 14 (50) 26 (79) 29 (88) 9 (27) 
23F 18 (64) 22 (79) 13 (46) 17 (52) 22 (67) 12 (36) 





















Figure 1. Impact of previous PPV23 vaccination and latent CMV on vaccine responses. CMV 
seropositivity was associated with lower Pn serotype-specific ARRs (A) and significantly lower whole 
vaccine PPV23 ARR (B) – CMV seropositive (+) in lilac, seronegative (-) in white. Pn serotype-specific 
(C) and whole vaccine (D) ARR were significantly lower in PPV23 revaccinees (red symbols) than 
PPV23 naive individuals (grey symbols). Spider diagrams show population medians, error bars 
denote medians and IQR. *denotes Mann Whitney 2-tailed p<0.05. 
 
Figure 2. Circulating total T cells and CD4+ phenotypes in patients with CKD and controls. T cell % of 
total lymphocytes (A), CD4/8 ratio (B) and “senescence”-associated populations (C-E) are shown for 
patients with CKD (blue) and controls (white). Comparison of Tfh-like (F), Th17-like (G) and Th1 % of 
CD4+ T cells between patients with CKD and controls is shown, with the latter defined by surface 
chemokine receptor expression (H) and intracellular IFNgamma/Tbet expression after overnight 
stimulation with aCD3/CD28/CD49d (I). Comparison of Th2 % of CD4 T cells between disease groups 
is shown as defined by surface chemokine receptor expression (J) and GATA3/IL-4 expression after 
overnight stimulation (K). Comparison of CD25+FoxP3+ (Treg) % of CD4 T cells is shown by study group 
(L). Surface chemokine receptor staining (panels F-H,J) was performed on fresh PBMCs obtained at 
baseline. All other phenotyping was performed using cryopreserved cells from baseline or month 6 
timepoints. Error bars denote median & IQR; *denotes Mann Whitney 2-tailed p<0.05.  
 
Figure 3. Impact of latent CMV infection on TIV response and circulating T cell phenotypes. Lower 
TIV mean ARRs were significantly associated with 3 CD4+ “senescence” and CMV-associated 
phenotypes (A-C). Latent CMV infection was associated with a lower CD4/8 ratio (D) and expansions 



















seronegative (-) – white symbols). Although CMV-seropositivity was associated with greater 
circulating Th1 populations (H), it did not appear to affect Th2 or Treg populations (I,J). *denotes Mann 
Whitney 2-tailed p<0.05 unless stated. 
Figure 4. Effects of CKD and latent CMV on plasma cell/blast generation following vaccination. B 
cell % of total B cells are shown for patients with CKD (blue) and controls (white) in panel A with 
representative gating and density plots (B) – baseline/month 6 cryopreserved PBMCs. The absolute 
change (C,D) and fold change (day 7/baseline, E, dotted line denotes no change) in circulating 
plasma cells/blasts (PC/Bs, defined as CD19+CD29+CD38high % of total B cells) are shown together 
with representative scatter plots at baseline and day 7 (F). PB/C fold change significantly correlated 
with vaccine response (G,H). CMV seropositivity was associated with significantly lower fold change 
in circulating plasma cells/blasts (I) and expansions of CD28null CD4+ T cells (phenotype associated 
with latent CMV infection) were significantly associated with smaller fold change of circulating PC/Bs 
at day 7 (J; Pearson’s statistics shown, performed on Normalised data). *denotes Mann Whitney 2-
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